{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:38:32Z","timestamp":1786804712487,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":770,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We previously reported the results of a prospective study of chemotherapy-induced nausea and vomiting (CINV) in a cohort of patients who received carboplatin-based chemotherapy and were selected from a nationwide registry of those scheduled for moderately (MEC) or highly emetogenic chemotherapy (HEC) by the CINV Study Group of Japan. Of 1,910 previously registered patients (HEC: 1,195; MEC: 715), 400 patients received carboplatin-based chemotherapy. The frequency of CINV was determined, and the risk factors for CINV were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>CINV data were collected from 7-day diaries. Risk factors for CINV were identified using logistic regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 400 patients scheduled for carboplatin-based chemotherapy, 267 patients received two antiemetics (5-hydroxytryptamine-3 receptor antagonist [5-HT3 RA] and dexamethasone [DEX]), 118 patients received three antiemetics (5-HT3 RA, DEX, and neurokinin-1 receptor antagonist [NK1 RA]), and 15 were nonadherent to the treatment. In these patients, the CINV overall, acute, and delayed phase rates of complete response (CR), defined as no vomiting with no rescue medication, were 67.0%, 98.2%, and 67.5%, respectively. The rates of no nausea were 55.6%, 94.0%, and 56.1%, respectively, and those of no vomiting were 81.3%, 99.0%, and 81.8%, respectively. Older age was associated with a decreased non-CR, whereas female sex, history of pregnancy-related emesis, and dual antiemetic therapy were associated with an increased non-CR during the overall period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a clinical practice setting, in patients who received carboplatin-based chemotherapy, adherence is quite high and appropriate antiemetic prophylaxis requires a triple antiemetic regimen including NK1 RA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0292","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:34:11Z","timestamp":1571682851000},"page":"e373-e380","source":"Crossref","is-referenced-by-count":21,"title":["A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan"],"prefix":"10.1093","volume":"25","author":[{"given":"Hirotoshi","family":"Iihara","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu, Japan"},{"name":"Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Cancer Biostatistics Laboratory, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[{"name":"Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aiba","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[{"name":"General Medical Research Center, Fukuoka University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"2021122510122129400_R1","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122510122129400_R2","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122510122129400_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","article-title":"Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: Executive summary","volume":"21","author":"Takeuchi","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2021122510122129400_R4"},{"key":"2021122510122129400_R5","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/cncr.30054","article-title":"Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy","volume":"122","author":"Hesketh","year":"2016","journal-title":"Cancer"},{"key":"2021122510122129400_R6","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1007\/s00520-018-4242-x","article-title":"Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: An exploratory analysis of a randomized phase III trial","volume":"26","author":"Weinstein","year":"2018","journal-title":"Support Care Cancer"},{"key":"2021122510122129400_R7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","article-title":"Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy","volume":"84","author":"Ito","year":"2014","journal-title":"Lung Cancer"},{"key":"2021122510122129400_R8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","article-title":"Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer","volume":"90","author":"Kusagaya","year":"2015","journal-title":"Lung Cancer"},{"key":"2021122510122129400_R9","first-page":"4527","article-title":"Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin","volume":"35","author":"Maehara","year":"2015","journal-title":"Anticancer Res"},{"key":"2021122510122129400_R10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","article-title":"A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70\u2009years receiving moderately emetogenic chemotherapy","volume":"109","author":"Tanioka","year":"2013","journal-title":"Br J Cancer"},{"key":"2021122510122129400_R11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","article-title":"Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: A multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin","volume":"21","author":"Yahata","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2021122510122129400_R12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: Results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2021122510122129400_R13","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122510122129400_R14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support Care Cancer"},{"key":"2021122510122129400_R15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support Care Cancer"},{"key":"2021122510122129400_R16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","article-title":"Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study","volume":"20","author":"Hilarius","year":"2012","journal-title":"Support Care Cancer"},{"key":"2021122510122129400_R17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci"},{"key":"2021122510122129400_R18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.18553\/jmcp.2012.18.5.385","article-title":"Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy","volume":"18","author":"Chan","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"2021122510122129400_R19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J Oncol Pract"},{"key":"2021122510122129400_R20"},{"key":"2021122510122129400_R21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-2753.2011.01665.x","article-title":"Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic","volume":"18","author":"Iihara","year":"2012","journal-title":"J Eval Clin Pract"},{"key":"2021122510122129400_R22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10147-015-0908-2","article-title":"Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy","volume":"21","author":"Iihara","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2021122510122129400_R23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7150\/jca.13637","article-title":"Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens","volume":"7","author":"Iihara","year":"2016","journal-title":"J Cancer"},{"key":"2021122510122129400_R24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/02841869009090058","article-title":"The natural course of emesis after carboplatin treatment","volume":"29","author":"Martin","year":"1990","journal-title":"Acta Oncol"},{"key":"2021122510122129400_R25","first-page":"24","article-title":"Olanzapine: An antiemetic option for chemotherapy-induced nausea and vomiting","volume":"5","author":"Brafford","year":"2014","journal-title":"J Adv Pract Oncol"},{"key":"2021122510122129400_R26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e373\/41920920\/oncolo_25_2_e373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e373\/41920920\/oncolo_25_2_e373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:13:28Z","timestamp":1640427208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/2\/e373\/6443404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,21]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0292","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,10,21]]}}}